Abstracts tagged "autoantibodies"

Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 813 • 2016 ACR/ARHP Annual Meeting
Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling
Petra Budde¹, Hans-Dieter Zucht¹, Heike Göhler¹, Klaus Marquart¹, Peter Schulz-Knappe¹, Matthias Schneider² and Nicolas Hunzelmann³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ³Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: Systemic sclerosis (SSc) is a remarkably heterogeneous autoimmune disease, for which effective disease-modifying therapies are still lacking. The most widely used classification divides SSc…
Abstract Number: 1900 • 2016 ACR/ARHP Annual Meeting
Anti-Topoisomerase Positive Systemic Sclerosis – Prognosis Infaust?
Maaike Boonstra¹, Gaia A. Beerends², Hans U. Scherer², Tom W.J. Huizinga¹ and Jeska K. de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-topoisomerase antibodies (ATA) in systemic sclerosis have been associated with poorer prognosis including diffuse skin involvement, pulmonary fibrosis, cardiac involvement and increased mortality. However,…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 1 • 2016 ACR/ARHP Annual Meeting
Factors Predicting Likelihood of Remaining Positive for Rheumatoid Arthritis-Related Autoantibodies Following Autoantibody Screening
Jill M. Norris¹, Elizabeth A. Bemis¹, M. Kristen Demoruelle², Michael Weisman³, Jane H. Buckner⁴, Peter K. Gregersen⁵, Ted R Mikuls⁶, James R. O'Dell⁶, Richard M. Keating⁷, Kevin D. Deane⁸ and V. Michael Holers⁸, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Feinstein Insititute for Medical Research, Manhasset, NY, ⁶Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Health, La Jolla, CA, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RA-related autoantibodies are typically elevated prior to the onset of RA. Screening for autoantibody (aAb) positive individuals is a means to assemble a cohort…
Abstract Number: 815 • 2016 ACR/ARHP Annual Meeting
The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc
Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Petra Budde¹, Hans-Dieter Zucht¹, Peter Schulz-Knappe¹, Prof. Dr. Matthias Schneider², Suzana Jordan³, Oliver Distler³, Britta Maurer³ and Nicolas Hunzelmann⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: To evaluate clinical associations of our recently discovered systemic sclerosis-specific auto-antigen BICD2 in clinically well characterized systemic sclerosis (SSc) cohorts from two tertiary referral…
Abstract Number: 1941 • 2016 ACR/ARHP Annual Meeting
Retrospective Survey of Concomitant Autoimmune Diseases and Autoantibodies in a Cohort of Patients with ANCA-Associated Vasculitis (AAV)
Marta Casal Moura^1,2, Sergio Prieto-González², Georgina Espígol-Frigolé², Giuseppe Murgia^2,3, Marco Alba², Jose Hernández-Rodríguez² and Maria C. Cid², ¹Department of Internal Medicine, São João Hospital Center, Porto, Portugal, ²Hospital Clínic. University of Barcelona. IDIBAPS, Vasculitis Research Unit. Department of Autoimmune Diseases, Spain, Barcelona, Spain, ³University Clinic for Visceral Surgery and Medicine Bauchzentrum Bern, Bern, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) - granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) have heterogenous clinic…
Abstract Number: 2871 • 2016 ACR/ARHP Annual Meeting
Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Teresa Aberle¹, Virginia C. Roberts¹, Joel M. Guthridge³, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael Weisman⁶, Mariko Ishimori⁶, Daniel J Wallace⁷, David Karp⁸, Kathy L. Sivils¹, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. Blood relatives (Rel) of lupus patients…
Abstract Number: 2 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Autoimmunity and Lumbar Bone Mineral Density in a Multi-Ethnic Community-Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Michael H. Criqui³, Ronit Katz⁴, Matthew Budoff⁵, Jon T. Giles⁶, Kiang Liu⁷ and Darcy S. Majka⁸, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴University of Washington, Seattle, WA, ⁵Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ⁶Rheumatology, Columbia University Medical Center, NY, NY, ⁷Department of Preventive Medicine, Northwestern University, Chicago, IL, ⁸Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies suggest that antibodies to citrullinated protein antigens (ACPA) contribute to decreased hand bone mineral density (BMD) in RA-free individuals. No evidence exists…
Abstract Number: 853 • 2016 ACR/ARHP Annual Meeting
Clinical Associations of Anti-Eukaryotic Initiation Factor 2B (anti-eIF2B) Antibodies in a Large Cohort of Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis
John Pauling^1,2, Hui Lu¹, Zoe Betteridge^1,2, Gloria Salazar³, Shervin Assassi³, Maureen D Mayes³ and Neil J. McHugh^1,4, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Autoantibodies can be characterized in up to 95% of patients with systemic sclerosis (SSc) and provide enormous diagnostic and prognostic value in the clinical…
Abstract Number: 2112 • 2016 ACR/ARHP Annual Meeting
Disease-Activity Associated Autoantibodies to Malondialdehyde-Modified Proteins Can be Isolated from Synovial B Cells in RA
Caroline Grönwall¹, Khaled Amara¹, Uta Hardt¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M Clancy³, Vivianne Malmström⁴ and Gregg J. Silverman³, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is a naturally occurring reactive aldehyde that arises during apoptosis or as a consequence of elevated reactive oxygen species and lipid peroxidation.…
Abstract Number: 2914 • 2016 ACR/ARHP Annual Meeting
Association of Radiographic Findings in Hand X-Ray with Autoantibodies in Patients with Systemic Sclerosis
Komei Sakata¹, Yuko Kaneko¹, Hidekata Yasuoka², Kunihiro Yamaoka² and Tsutomu Takeuchi³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Musculoskeletal involvement is a major complication for patients with systemic sclerosis (SSc). Various radiographic abnormalities are observed, especially in hands, however, the detailed prevalence…
Abstract Number: 163 • 2016 ACR/ARHP Annual Meeting
Fluorescence Optical Imaging Reveals Distinct Patterns of Hand Joint Inflammation in Seropositive and Seronegative Early Rheumatoid Arthritis
Yogan Kisten¹, Erik af Klint², Hamed Rezaei^2,3, Adrian Levitsky⁴, Per T Larsson², Anna Karlsson^2,3, Noémi Györi¹, Ronald F. van Vollenhoven^1,5 and Laurent Arnaud³, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁵Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands
Background/Purpose: Detection of abnormal Rheumatoid Arthritis (RA) related autoantibodies, Rheumatoid Factor (RF) and Anti- Citrullinated Peptide Antibody (ACPA), along with musculoskeletal ultrasound (MSUS) plays a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.